MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70416

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.

Burns Jeffrey M, Morris Jill K, Vidoni Eric D, Wilkins Heather M, Choi In-Young, Lee Phil, Hunt Suzanne L, Mahnken Jonathan D, Brooks William M, Lepping Rebecca J, Gupta Aditi, Esterline Russell, Oscarsson Jan, Swerdlow Russell H

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Due to its metabolic effects, dapagliflozin, a sodium-glucose transporter 2 (SGLT2) inhibitor, holds potential as an Alzheimer's disease (AD) therapeutic.

METHODS

We conducted a double-blind, randomized, placebo-controlled, parallel-group, 12-week single-site study to investigate the effect of dapagliflozin in participants with probable AD (Mini-Mental State Examination [MMSE] score 15-26). We planned to enroll 48 participants with 2:1 randomization to 10 mg dapagliflozin once daily (n = 32) versus matching placebo (n = 16). The primary objective was the effect of dapagliflozin on cerebral N-acetylaspartate (NAA). We also assessed safety, glycemic control, body composition, brain metabolism, and cognition.

RESULTS

There was no change in the primary outcome. There were no significant adverse event differences. Hemoglobin A1c, fat mass, and fat-free lean mass decreased; brain glutathione increased; and Stroop Interference test (but not other cognitive test) performance improved.

DISCUSSION: Treated participants manifested metabolic effects observed in clinical studies of other cohorts. In AD, dapagliflozin use may affect the brain.

HIGHLIGHTS: Dapagliflozin did not alter magnetic resonance spectroscopy N-acetylaspartate (primary outcome) in this exploratory Alzheimer's disease (AD) trial. Dapagliflozin-induced glucose disposal is sufficient to alter systemic metabolism. AD patients taking dapagliflozin exhibited metabolic effects seen in diabetics.

Для цитирования: Burns Jeffrey M, Morris Jill K, Vidoni Eric D, Wilkins Heather M, Choi In-Young, Lee Phil, Hunt Suzanne L, Mahnken Jonathan D, Brooks William M, Lepping Rebecca J, Gupta Aditi, Esterline Russell, Oscarsson Jan, Swerdlow Russell H. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70416.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.